- ICH GCP
- Registr klinických studií v USA
- Klinická studie NCT02770001
Suitability of Some Data Quality Controls Thresholds for Genetic Association Studies of Admixed Population
Investigating the Suitability of Some Data Quality Controls Thresholds for Genetic Association Studies of Admixed Population
Background: In genetic studies, the quality of DNA samples is tested first. Samples that are low-quality are not used. Some studies involve minority ethnic groups. And example is admixed African American. These studies often have small sample sizes. It is important to make sure samples are not discarded unnecessarily. This may happen by using quality control (QC) thresholds for homogenous groups. These may not be appropriate for an admixed group. Researchers want to study samples that failed certain QC tests. They want to see if this has to do with the ancestry of the outliers or the quality of the samples.
Objectives:
To study samples that fail heterozygosity and sample genotype call rate QC. To see if the failing rates have to do with the ancestry composition of the outliers or the quality of the samples.
Eligibility:
No new participants. Researchers will review data that has already been collected.
Design:
Researchers will study DNA samples in a lab.
The samples will not include data that can identify the person the sample came from.
Přehled studie
Postavení
Podmínky
Detailní popis
The purpose of this IRB proposal is to gain access to genetic data generated from participants of publically-funded genomic studies and deposited into dbGaP. It is our intention to use dbGaP data to conduct secondary analysis of the influence of admixture on the outcome of data quality control (QC) in genetic association studies to inform future studies of the optimal QC metric for the genetic association analysis of admixed population. The data we intend to use is deposited in dbGaP and is from the Michigan University Health and Retirement Study (HRS). This protocol is being sent to you because of a dbGaP requirement for this specific de-identified dataset to be reviewed by an IRB as that was not in the protocol.
This work will require the use of statistical analyses tools to estimate the genetic ancestry make-up of each sample, from the genotype data, and determine how that ancestry relates to QC outcomes (i.e. whether or not the sample might be excluded from an analysis due to its ancestral genetic composition rather that the sample genetic quality).
Objectives and specific aims: This work aims to investigate samples failing heterozygosity and sample genotype call rate quality control (QC) to determine whether or not the samples call rate and heterozygosity rate have to do with the ancestry composition of the outliers rather than the quality of the samples and inform future studies of potential loss if general QC is applied to genetic data of admixed sample sets.
Rationale and Background: In genetic association studies DNA sample quality can vary largely across study participants and such variation has an impact on genotype call rate and genotype accuracy; samples of low DNA quality tend to have lower genotype call rate and genotype accuracy. Heterozygosity rate (proportion of heterozygous loci per individual) and genotype failure rate (proportion of missing genotypes per individual) are jointly and routinely used to identify samples with low DNA quality at the data quality control (QC) stage of genetic association studies. Excessive heterozygosity rate may indicate sample contamination whilst a reduced heterozygosity rate could indicate inbreeding [1]. Samples with 3-7% [2,3] genotype call-rate and heterozygosity > 2-3 standard deviations from the mean heterozygosity are usually excluded from genetic case-control studies.
Generally, the sample size of genetic association studies involving minority ethnic groups such as admixed African American tends to be small. It is hence important to ensure samples are not discarded unnecessarily, resulting into reduced statistical power, by using QC thresholds applied to homogenous groups which might not be appropriate for an admixed sample set. The aim of this analysis is to investigate samples failing heterozygosity and sample genotype call rate QC to determine whether or not the samples call rate and heterozygosity rate have to do with the ancestry composition of the outliers rather than the quality of the samples. The motivation is to inform future studies of potential loss if general
Typ studie
Kritéria účasti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
- All the genotype data will be used and no individual will be excluded based on any phenotype.
Studijní plán
Jak je studie koncipována?
Detaily designu
Co je měření studie?
Primární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Continental genetic ancestry fraction
Časové okno: Study Completion
|
Study Completion
|
Sekundární výstupní opatření
Měření výsledku |
Časové okno |
---|---|
Heterozygosity rate
Časové okno: Study Completion
|
Study Completion
|
Spolupracovníci a vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Sharon K Davis, National Human Genome Research Institute (NHGRI)
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia
Primární dokončení (Aktuální)
Dokončení studie (Aktuální)
Termíny zápisu do studia
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Odhad)
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Více informací
Termíny související s touto studií
Klíčová slova
Další identifikační čísla studie
- 999916110
- 16-HG-N110
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .
Klinické studie na African American Genetics
-
Queens College, The City University of New YorkNáborZveřejnění článků předložených American Journal of Public HealthSpojené státy
-
Georgetown UniversityNational Cancer Institute (NCI); American Cancer Society, Inc.; Susan G. Komen...DokončenoStudujte čínské ženy, které nedodržovaly pokyny pro mamografický screening American Cancer SocietySpojené státy
-
University of UtahNational Cancer Institute (NCI)NáborÚnava | Sedavý životní styl | Metastatický karcinom prostaty | Fáze IV rakoviny prostaty AJCC (American Joint Committee on Cancer) v8 | Fáze IVA rakoviny prostaty AJCC (American Joint Committee on Cancer) v8 | Fáze IVB Rakovina prostaty AJCC (American Joint Committee on Cancer) v8Spojené státy
-
Jonsson Comprehensive Cancer CenterZatím nenabírámeKarcinom prostaty | Fáze IVB rakoviny prostaty American Joint Committee on Cancer (AJCC) v8Spojené státy
-
Rashmi Verma, MDNational Cancer Institute (NCI)NáborKarcinom prostaty odolný proti kastraci | Metastatický adenokarcinom prostaty | Fáze IVB rakoviny prostaty American Joint Committee on Cancer (AJCC) v8Spojené státy
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI); National Institutes of Health (NIH)NáborAnatomický karcinom prsu stadia II AJCC v8 | Anatomický karcinom prsu stadia III AJCC v8 | Rané stadium karcinomu prsu | Anatomic Stage I Breast Cancer American Joint Committee on Cancer (AJCC) v8Spojené státy
-
Jonsson Comprehensive Cancer CenterSilicon Valley Community FoundationNáborStádium IV rakoviny slinivky břišní AJCC v8 | Neresekabilní adenokarcinom pankreatu | Fáze III rakoviny pankreatu American Joint Committee on Cancer (AJCC) v8Spojené státy
-
University of Southern CaliforniaNational Cancer Institute (NCI)Zatím nenabírámeMaligní solidní novotvar | Karcinom prsu | Metastatický karcinom prostaty | Karcinom vaječníků | Triple-negativní karcinom prsu | Mužský karcinom prsu | Exokrinní novotvar pankreatu | Fáze IVB rakoviny prostaty American Joint Committee on Cancer v8Spojené státy
-
Jonsson Comprehensive Cancer CenterViewray Inc.Aktivní, ne náborProgrese PSA | Adenokarcinom prostaty stadia III AJCC v7 | Adenokarcinom prostaty AJCC v7 | Úroveň PSA vyšší než 0,03 | Adenokarcinom prostaty I. fáze AJCC (American Joint Committee on Cancer) v7Spojené státy
-
Jonsson Comprehensive Cancer CenterUkončenoKarcinom prostaty odolný proti kastraci | Metastatický karcinom prostaty | Fáze IVA rakoviny prostaty AJCC v8 | Stádium IVB rakoviny prostaty AJCC v8 | Fáze IV rakoviny prostaty American Joint Committee on Cancer (AJCC) v8Spojené státy